Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1722-1728

  Fernández Martos, Carlos ^a   Garcia Albeniz, X ^b   Pericay, C ^c   Maurel, J ^d   Aparicio, J ^e   Montagut, C ^f   Safont, M J ^g   Salud, A ^h   Vera, R ⁱ   Massuti, B ^j   Escudero, P ^k   Alonso, V ^l   Bosch, C ^m   Martin, M ⁿ   Minsky, B D ^o  

^a Valencian Institute of Pediatric Neurology   (Spain)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HOSPITAL DE SABADELL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^h HOSPITAL ARNAU DE VILANOVA   (Spain)

ⁱ Universidad Pública de Navarra   (Spain)

^j GENERAL HOSPITAL   (Spain)

^k Lozano Blesa Hospital   (Spain)

^l HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^m Gynecology Department   (Spain)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Adjuvant chemotherapy; Induction chemotherapy; Locally advanced rectal cancer; Phase II randomized trial

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; LOCAL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; RECTUM RESECTION; SPAIN; TOTAL MESORECTAL EXCISION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROCEDURES; RECTAL NEOPLASMS; RECTUM; SURGERY; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; RECTUM;

EID: 84941646346     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv223     Document Type: Article

References (13)

1. Bosset JF, Calais G, Mineur L et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190.
2. Glynne-Jones R, Counsell N, Quirke P et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014; 25: 1356-1362.
3. Sainato A, Cernusco Luna Lunzia V, Valentini V et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 2014; 113: 223-229.
4. Breugom AJ, van Gijn W, Muller EW et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomised phase III trial. Ann Oncol 2015; 26: 696-701.
5. Hong Y, Nam B, Kim K et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-1253.
6. Fernández-Martos C, Pericay C, Aparicio J et al. Phase II, randomized study of concomitant chemoradiation followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiation and surgery in magnetic resonance imaging defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 2010; 28: 859-865.
7. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (14 May 2015, date last accessed). Version 2. 2015.
8. Glimelius B, Pahlman L, Cervantes A and on behalf of ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v82-v86.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
10. Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow up of 11 years. J Clin Oncol 2012; 30(16): 1926-1933.
11. Sclafani F, Gonzalez D, Cunningham D et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. JNCI 2014; 106(7): dju121.
12. Ahmed S, Ahmad I, Zhu T et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum 2010; 53(10): 1432-1438.
13. Roh M, Colangelo L, O'Connell M et al. Preoperative multimodality therapy improves diseasefree survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-5130.